Tagraxofusp and pacritinib for myelofibrosis after JAK inhibitor
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a new combination of two drugs, tagraxofusp and pacritinib, for people with myelofibrosis who have already tried a JAK inhibitor without enough benefit or who couldn't take one. The goal is to see if the combination can shrink the spleen and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myelofibrosis (a type of bone marrow disorder) and are at intermediate-2 or high risk.
- You have already tried a JAK inhibitor (like ruxolitinib) for at least 3 months, and it didn't help enough or you couldn't take it.
- You have significant myelofibrosis symptoms, such as an enlarged spleen, severe itching, night sweats, bone pain, or low blood counts.
- You have not been treated with tagraxofusp or pacritinib before.
- Your kidney and liver function are adequate, and your heart is working well (ejection fraction of 50% or more).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
This trial tests a new combination of two drugs, roginolisib and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough with ruxolitinib alone. It aims to see if adding roginolisib can improve symptoms and spleen size.
This study looks at how well pacritinib works in everyday medical care for people with myelofibrosis, a type of bone marrow cancer that causes scarring. It reviews medical records to understand treatment effects, which may help guide future care decisions.
This trial tests a new combination of two drugs (axatilimab and ruxolitinib) for people with myelofibrosis or a related blood cancer called CMML. The goal is to see if the combination works better than standard treatments for these diseases.
This trial is studying the effectiveness of momelotinib, a JAK inhibitor, for people with myelofibrosis who have an enlarged spleen. It aims to see how well the drug works in real-world practice.
This trial tests a new oral medicine, flonoltinib maleate, to see if it can help reduce spleen size and improve symptoms in people with myelofibrosis, a type of blood disorder. The study enrolls patients who have not responded to other treatments or have not had JAK inhibitor therapy (or only briefly).
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.